Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD.

Eur Heart J. 2014 Apr;35(14):932-41. doi: 10.1093/eurheartj/eht302. Epub 2013 Aug 29.

2.

Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.

Musolino V, Palus S, Tschirner A, Drescher C, Gliozzi M, Carresi C, Vitale C, Muscoli C, Doehner W, von Haehling S, Anker SD, Mollace V, Springer J.

J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):555-566. Epub 2016 Apr 7.

3.
4.

Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.

Tsukashita M, Marui A, Nishina T, Yoshikawa E, Kanemitsu H, Wang J, Ikeda T, Komeda M.

J Thorac Cardiovasc Surg. 2008 Jul;136(1):58-64. doi: 10.1016/j.jtcvs.2007.11.016. Epub 2008 May 7.

5.

Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.

Trobec K, Palus S, Tschirner A, von Haehling S, Doehner W, Lainscak M, Anker SD, Springer J.

Nutrition. 2014 Sep;30(9):1069-75. doi: 10.1016/j.nut.2013.12.005. Epub 2013 Dec 14.

PMID:
24976415
6.

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.

Anker SD, Coats AJ.

Chest. 1999 Mar;115(3):836-47. Review.

PMID:
10084500
8.

Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.

Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA.

Circ Heart Fail. 2010 May;3(3):347-53. doi: 10.1161/CIRCHEARTFAILURE.109.906909. Epub 2010 Mar 18.

9.

[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].

Brilla CG, Schencking M, Scheer C, Rupp H.

Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Review. German.

PMID:
9198851
10.

Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.

Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.

J Card Fail. 2012 Apr;18(4):265-81. doi: 10.1016/j.cardfail.2012.02.005.

PMID:
22464767
11.

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C.

Eur Heart J. 2008 Sep;29(17):2171-9. doi: 10.1093/eurheartj/ehn277. Epub 2008 Jun 27.

PMID:
18586661
12.

Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.

Han SW, Choi SW, Ryu KH, Kim HJ, Kim SH, Shim WJ, Cha TJ, Choi DJ, Kim YJ, Yoo BS, Kim JH, Hwang KK, Jeon H, Shin MS.

Cardiovasc Ther. 2016 Jun;34(3):172-9. doi: 10.1111/1755-5922.12185.

PMID:
27003232
13.

Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.

Muñoz-Pacheco P, Ortega-Hernández A, Caro-Vadillo A, Casanueva-Eliceiry S, Aragoncillo P, Egido J, Fernández-Cruz A, Gómez-Garre D.

J Hypertens. 2013 Nov;31(11):2309-18; discussion 2319. doi: 10.1097/HJH.0b013e328364abd6.

PMID:
24077250
14.

A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.

Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH.

JACC Cardiovasc Imaging. 2011 Dec;4(12):1239-49. doi: 10.1016/j.jcmg.2011.08.014.

15.

Metabolic and immunologic derangements in cardiac cachexia: where to from here?

Strassburg S, Anker SD.

Heart Fail Rev. 2006 Mar;11(1):57-64. Review.

PMID:
16819578
16.

Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia.

Saitoh M, Hatanaka M, Konishi M, Ishida J, Palus S, Ebner N, Döhner W, von Haehling S, Anker SD, Springer J.

Int J Cardiol. 2016 Sep 1;218:312-317. doi: 10.1016/j.ijcard.2016.05.008. Epub 2016 May 14.

PMID:
27240157
17.

Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.

de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A.

Circ Heart Fail. 2012 Jan;5(1):97-105. doi: 10.1161/CIRCHEARTFAILURE.111.964494. Epub 2011 Dec 9.

18.

Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.

Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D, González-Toledo R, Rebollar-González V, Narváez-David R, Dorantes-García J.

Rev Invest Clin. 2007 Mar-Apr;59(2):103-7.

PMID:
17633796
19.

Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats.

Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C, Katus HA, Haass M.

Endocrinology. 2006 May;147(5):2526-34. Epub 2006 Jan 26.

PMID:
16439456
20.

Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure.

Rengo G, Lymperopoulos A, Zincarelli C, Femminella G, Liccardo D, Pagano G, de Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone Filardi P, Koch W, Leosco D.

Br J Pharmacol. 2012 Aug;166(8):2430-40. doi: 10.1111/j.1476-5381.2012.01972.x.

Supplemental Content

Support Center